Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Pirfenidone [USAN:INN]
RN: 53179-13-8
UNII: D7NLD2JX7U
InChIKey: ISWRGOKTTBVCFA-UHFFFAOYSA-N

Note

  • Note: An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal, platelet-derived, and transforming beta-1 growth factors, thereby slowing tumor cell proliferation. This agent also inhibits DNA synthesis and the production of mRNA for collagen types I and III, resulting in a reduction in radiation-induced fibrosis. (NCI Thesaurus)

Molecular Formula

  • C12-H11-N-O

Molecular Weight

  • 185.225
 

Classification Codes

  • Analgesic
  • Analgesics
  • Analgesics, Non-Narcotic
  • Anti-Inflammatory
  • Anti-Inflammatory Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antineoplastic Agents
  • Antipyretic
  • Antirheumatic Agents
  • Central Nervous System Agents
  • Drug / Therapeutic Agent
  • Peripheral Nervous System Agents
  • Sensory System Agents

Names and Synonyms

Name of Substance

  • Pirfenidone
  • Pirfenidone [USAN:INN]

Synonyms

  • 5-21-07-00197 (Beilstein Handbook Reference)
  • 5-Methyl-1-phenyl-2(1H)-pyridone
  • AMR 69
  • AMR-69
  • BRN 1526549
  • Deskar
  • Esbriet
  • HSDB 8340
  • Pirespa
  • Pirfenidona
  • Pirfenidona [INN-Spanish]
  • Pirfenidone
  • Pirfenidonum
  • Pirfenidonum [INN-Latin]
  • UNII-D7NLD2JX7U

Systematic Names

  • 2(1H)-Pyridinone, 5-methyl-1-phenyl-
  • 2(1H)-Pyridone, 5-methyl-1-phenyl-

Registry Numbers

CAS Registry Number

  • 53179-13-8

FDA UNII

  • D7NLD2JX7U

System Generated Number

  • 0053179138

Structure Descriptors

InChI

1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3

InChIKey

ISWRGOKTTBVCFA-UHFFFAOYSA-N

Smiles

n1(c2ccccc2)c(ccc(c1)C)=O

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
cat LD50 intravenous 40mg/kg (40mg/kg)   European Patent Application. Vol. #383591,
cat LD50 oral 500mg/kg (500mg/kg)   European Patent Application. Vol. #383591,
dog LD50 intravenous 200mg/kg (200mg/kg)   European Patent Application. Vol. #383591,
dog LD50 oral 300mg/kg (300mg/kg)   European Patent Application. Vol. #383591,
guinea pig LD50 intraperitoneal 460mg/kg (460mg/kg)   European Patent Application. Vol. #383591,
guinea pig LD50 oral 810mg/kg (810mg/kg)   European Patent Application. Vol. #383591,
monkey LD50 intravenous 100mg/kg (100mg/kg)   European Patent Application. Vol. #383591,
mouse LD50 intraperitoneal 420mg/kg (420mg/kg)   United States Patent Document. Vol. #3974281,
mouse LD50 intravenous 285mg/kg (285mg/kg)   European Patent Application. Vol. #383591,
mouse LD50 oral 580mg/kg (580mg/kg)   United States Patent Document. Vol. #4042699,
rabbit LD50 intravenous 280mg/kg (280mg/kg)   European Patent Application. Vol. #383591,
rat LD50 intraperitoneal 430mg/kg (430mg/kg)   European Patent Application. Vol. #383591,
rat LD50 oral 1295mg/kg (1295mg/kg)   European Patent Application. Vol. #383591,